4 terminated. 4 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 4 | Terminated 4 |
Follow Thyroid Eye Disease: new trials by email Literature Review of Thyroid Eye Disease trials Research Report on Thyroid Eye Disease
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease. Efgartigimod PH20 SC, Placebo PH20 SC - Thyroid Eye Disease | Phase 3 | Terminated | argenx | 105 | 2024-03-28 | 2026-03-16 |
| A Study of Efgartigimod PH20 SC Given by Prefilled Syringe in Adults With Thyroid Eye Disease Efgartigimod PH20 SC, Placebo PH20 SC - Thyroid Eye Disease | Phase 3 | Terminated | argenx | 102 | 2024-03-27 | 2026-03-16 |
| Extension Study to Assess Batoclimab in Participants With Thyroid Eye Disease Observational cohort study, Batoclimab - Thyroid Eye Disease | Phase 3 | Terminated | Immunovant Sciences GmbH | 109 | 2022-11-06 | 2026-04-29 |
| A Study of the Efficacy and Safety of Secukinumab 300 mg in Patients With Thyroid Eye Disease (TED) Secukinumab, Placebo - Thyroid Eye Disease, Graves Orbitopathy | Phase 3 | Terminated | Novartis Pharmaceuticals | 28 | 2021-11-29 | 2026-04-15 |
Graves Ophthalmopathy (4) · Autoimmune Diseases (1) · Exophthalmos (1)
Congenital, Hereditary, and Neonatal Diseases and Abnormalities (4) · Endocrine System Diseases (4) · Eye Diseases (4) · Eye Diseases, Hereditary (4) · Genetic Diseases, Inborn (4) · Goiter (4) · Graves Disease (4) · Hyperthyroidism (4) · Immune System Diseases (4) · Orbital Diseases (4) · Thyroid Diseases (4) · Autoimmune Diseases (3) · Exophthalmos (3)
secukinumab (1)
argenx (2) · Immunovant Sciences GmbH (1) · Novartis Pharmaceuticals (1)
Germany (3) · Italy (3) · Spain (3) · United Kingdom (3) · United States (3) · Australia (2) · Belgium (2) · Bulgaria (2) · China (2) · Georgia (2) · Hungary (2) · Latvia (2) · Poland (2) · Austria (1) · Czechia (1)
2023 (2)